{ "@graph": [    { "@id": "http://linked.opendata.cz/resource/ATC/C",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "Kardiovaskul\u00E1rn\u00ED syst\u00E9m" , "@language" : "cs" } ,        { "@value" : "CARDIOVASCULAR SYSTEM" , "@language" : "en" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "C" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/C09",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM" , "@language" : "en" } ,        { "@value" : "L\u00E9\u010Diva ovliv\u0148uj\u00EDc\u00ED renin-angiotenzinov\u00FD syst\u00E9m" , "@language" : "cs" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "C09" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/C09C",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "Antagonist\u00E9 angiotensinu II, samotn\u00ED" , "@language" : "cs" } ,        { "@value" : "ANGIOTENSIN II ANTAGONISTS, PLAIN" , "@language" : "en" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "C09C" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/C09CA",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "Antagonist\u00E9 angiotensinu II, samotn\u00ED" , "@language" : "cs" } ,        { "@value" : "Angiotensin II antagonists, plain" , "@language" : "en" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "C09CA" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/C09CA01",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://www.w3.org/2004/02/skos/core#broaderTransitive" : [ "http://linked.opendata.cz/resource/ATC/C09CA" ,        "http://linked.opendata.cz/resource/ATC/C09" ,        "http://linked.opendata.cz/resource/ATC/C" ,        "http://linked.opendata.cz/resource/ATC/C09C" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "Losartan" , "@language" : "en" } ,        { "@value" : "Losartan" , "@language" : "cs" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "C09CA01" } ] } ,    { "@id": "http://linked.opendata.cz/resource/drug-encyclopedia/ingredient/M0351838",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/Ingredient" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Losartan potassium" , "@language" : "cs" } ,        { "@value" : "Losartan potassium" , "@language" : "en" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPharmacologicalAction" : [ "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0001456" ,        "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0456879" ,        "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0001326" ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product/APO-LOSARTAN-12-5-MG",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProduct" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasActiveIngredient" : [ "http://linked.opendata.cz/resource/drug-encyclopedia/ingredient/M0351838" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "APO-LOSARTAN 12,5 MG" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/C09CA01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasMedicinalProductPackaging" : [ "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0121348" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0121349" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0121354" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0121353" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0121352" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0121350" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0121347" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0121351" ] } ,    { "@id": "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0001326",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/PharmacologicalAction" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Anti-arrhythmia agents" , "@language" : "en" } ,        { "@value" : "Antiarytmika" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/description" : [ { "@value" : "Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.     " , "@language" : "en" } ] } ,    { "@id": "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0001456",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/PharmacologicalAction" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Antihypertensive agents" , "@language" : "en" } ,        { "@value" : "Antihypertenz\u00EDva" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/description" : [ { "@value" : "Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.     " , "@language" : "en" } ] } ,    { "@id": "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0456879",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/PharmacologicalAction" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Angiotensin ii type 1 receptor blockers" , "@language" : "en" } ,        { "@value" : "Blok\u00E1tory receptoru 1 pro angiotenzin ii" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/description" : [ { "@value" : "Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.     " , "@language" : "en" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0121348",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "APO-LOSARTAN 12,5 MG" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/C09CA01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "HYPOTENSIVA" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC159656_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "28" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Peror\u00E1ln\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "12.5MG" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : "-\tL\u00E9\u010Dba esenci\u00E1ln\u00ED hypertenze u dosp\u011Bl\u00FDch a d\u011Bt\u00ED a dosp\u00EDvaj\u00EDc\u00EDch ve v\u011Bku 6 a\u017E 18 let.\n-\tL\u00E9\u010Dba ren\u00E1ln\u00EDho onemocn\u011Bn\u00ED u pacient\u016F s\u00A0hypertenz\u00ED a diabetes mellitus 2. typu s\u00A0protein\u00FAri\u00ED \u2265\u00A00,5 g/den jako sou\u010D\u00E1st antihypertenzn\u00ED l\u00E9\u010Dby.\n-        L\u00E9\u010Dba chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED (u pacient\u016F \u2265 60 let), kdy\u017E l\u00E9\u010Dba inhibitory angiotenzin konvertuj\u00EDc\u00EDho enzymu (ACE ) nen\u00ED pova\u017Eov\u00E1na za vhodnou v d\u016Fsledku inkompatibility, zejm\u00E9na ka\u0161le, nebo kontraindikac\u00ED.  Pacienti se srde\u010Dn\u00EDm selh\u00E1n\u00EDm, kte\u0159\u00ED byli stabilizov\u00E1ni pomoc\u00ED ACE inhibitoru nesm\u011Bj\u00ED b\u00FDt na losartan p\u0159ev\u00E1d\u011Bni. Pacienti mus\u00ED m\u00EDt ejek\u010Dn\u00ED frakci lev\u00E9 komory \u2264 40 % a mus\u00ED b\u00FDt klinicky stabiln\u00ED a mus\u00ED m\u00EDt stanoven\u00FD l\u00E9\u010Debn\u00FD re\u017Eim pro chronick\u00E9 srde\u010Dn\u00ED selh\u00E1n\u00ED.\n-\tSn\u00ED\u017Een\u00ED rizika c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody u hypertonik\u016F s\u00A0hypertrofi\u00ED lev\u00E9 komory dokumentovan\u00E9 na EKG (viz bod 5.1 Studie LIFE, rasa).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "POR TBL FLM 28X12.5MG" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0121349",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "APO-LOSARTAN 12,5 MG" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/C09CA01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "HYPOTENSIVA" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC159656_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "30" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Peror\u00E1ln\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "12.5MG" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : "-\tL\u00E9\u010Dba esenci\u00E1ln\u00ED hypertenze u dosp\u011Bl\u00FDch a d\u011Bt\u00ED a dosp\u00EDvaj\u00EDc\u00EDch ve v\u011Bku 6 a\u017E 18 let.\n-\tL\u00E9\u010Dba ren\u00E1ln\u00EDho onemocn\u011Bn\u00ED u pacient\u016F s\u00A0hypertenz\u00ED a diabetes mellitus 2. typu s\u00A0protein\u00FAri\u00ED \u2265\u00A00,5 g/den jako sou\u010D\u00E1st antihypertenzn\u00ED l\u00E9\u010Dby.\n-        L\u00E9\u010Dba chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED (u pacient\u016F \u2265 60 let), kdy\u017E l\u00E9\u010Dba inhibitory angiotenzin konvertuj\u00EDc\u00EDho enzymu (ACE ) nen\u00ED pova\u017Eov\u00E1na za vhodnou v d\u016Fsledku inkompatibility, zejm\u00E9na ka\u0161le, nebo kontraindikac\u00ED.  Pacienti se srde\u010Dn\u00EDm selh\u00E1n\u00EDm, kte\u0159\u00ED byli stabilizov\u00E1ni pomoc\u00ED ACE inhibitoru nesm\u011Bj\u00ED b\u00FDt na losartan p\u0159ev\u00E1d\u011Bni. Pacienti mus\u00ED m\u00EDt ejek\u010Dn\u00ED frakci lev\u00E9 komory \u2264 40 % a mus\u00ED b\u00FDt klinicky stabiln\u00ED a mus\u00ED m\u00EDt stanoven\u00FD l\u00E9\u010Debn\u00FD re\u017Eim pro chronick\u00E9 srde\u010Dn\u00ED selh\u00E1n\u00ED.\n-\tSn\u00ED\u017Een\u00ED rizika c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody u hypertonik\u016F s\u00A0hypertrofi\u00ED lev\u00E9 komory dokumentovan\u00E9 na EKG (viz bod 5.1 Studie LIFE, rasa).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "POR TBL FLM 30X12.5MG" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0121354",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "APO-LOSARTAN 12,5 MG" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/C09CA01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "HYPOTENSIVA" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC159656_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "100" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Peror\u00E1ln\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "12.5MG" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : "-\tL\u00E9\u010Dba esenci\u00E1ln\u00ED hypertenze u dosp\u011Bl\u00FDch a d\u011Bt\u00ED a dosp\u00EDvaj\u00EDc\u00EDch ve v\u011Bku 6 a\u017E 18 let.\n-\tL\u00E9\u010Dba ren\u00E1ln\u00EDho onemocn\u011Bn\u00ED u pacient\u016F s\u00A0hypertenz\u00ED a diabetes mellitus 2. typu s\u00A0protein\u00FAri\u00ED \u2265\u00A00,5 g/den jako sou\u010D\u00E1st antihypertenzn\u00ED l\u00E9\u010Dby.\n-        L\u00E9\u010Dba chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED (u pacient\u016F \u2265 60 let), kdy\u017E l\u00E9\u010Dba inhibitory angiotenzin konvertuj\u00EDc\u00EDho enzymu (ACE ) nen\u00ED pova\u017Eov\u00E1na za vhodnou v d\u016Fsledku inkompatibility, zejm\u00E9na ka\u0161le, nebo kontraindikac\u00ED.  Pacienti se srde\u010Dn\u00EDm selh\u00E1n\u00EDm, kte\u0159\u00ED byli stabilizov\u00E1ni pomoc\u00ED ACE inhibitoru nesm\u011Bj\u00ED b\u00FDt na losartan p\u0159ev\u00E1d\u011Bni. Pacienti mus\u00ED m\u00EDt ejek\u010Dn\u00ED frakci lev\u00E9 komory \u2264 40 % a mus\u00ED b\u00FDt klinicky stabiln\u00ED a mus\u00ED m\u00EDt stanoven\u00FD l\u00E9\u010Debn\u00FD re\u017Eim pro chronick\u00E9 srde\u010Dn\u00ED selh\u00E1n\u00ED.\n-\tSn\u00ED\u017Een\u00ED rizika c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody u hypertonik\u016F s\u00A0hypertrofi\u00ED lev\u00E9 komory dokumentovan\u00E9 na EKG (viz bod 5.1 Studie LIFE, rasa).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "POR TBL FLM 100X12.5MG" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0121353",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "APO-LOSARTAN 12,5 MG" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/C09CA01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "HYPOTENSIVA" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC159656_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "30" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Peror\u00E1ln\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "12.5MG" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : "-\tL\u00E9\u010Dba esenci\u00E1ln\u00ED hypertenze u dosp\u011Bl\u00FDch a d\u011Bt\u00ED a dosp\u00EDvaj\u00EDc\u00EDch ve v\u011Bku 6 a\u017E 18 let.\n-\tL\u00E9\u010Dba ren\u00E1ln\u00EDho onemocn\u011Bn\u00ED u pacient\u016F s\u00A0hypertenz\u00ED a diabetes mellitus 2. typu s\u00A0protein\u00FAri\u00ED \u2265\u00A00,5 g/den jako sou\u010D\u00E1st antihypertenzn\u00ED l\u00E9\u010Dby.\n-        L\u00E9\u010Dba chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED (u pacient\u016F \u2265 60 let), kdy\u017E l\u00E9\u010Dba inhibitory angiotenzin konvertuj\u00EDc\u00EDho enzymu (ACE ) nen\u00ED pova\u017Eov\u00E1na za vhodnou v d\u016Fsledku inkompatibility, zejm\u00E9na ka\u0161le, nebo kontraindikac\u00ED.  Pacienti se srde\u010Dn\u00EDm selh\u00E1n\u00EDm, kte\u0159\u00ED byli stabilizov\u00E1ni pomoc\u00ED ACE inhibitoru nesm\u011Bj\u00ED b\u00FDt na losartan p\u0159ev\u00E1d\u011Bni. Pacienti mus\u00ED m\u00EDt ejek\u010Dn\u00ED frakci lev\u00E9 komory \u2264 40 % a mus\u00ED b\u00FDt klinicky stabiln\u00ED a mus\u00ED m\u00EDt stanoven\u00FD l\u00E9\u010Debn\u00FD re\u017Eim pro chronick\u00E9 srde\u010Dn\u00ED selh\u00E1n\u00ED.\n-\tSn\u00ED\u017Een\u00ED rizika c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody u hypertonik\u016F s\u00A0hypertrofi\u00ED lev\u00E9 komory dokumentovan\u00E9 na EKG (viz bod 5.1 Studie LIFE, rasa).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasResumedMarketingDate" : [ { "@value" : "2010-06-30" , "@type" : "http://www.w3.org/2001/XMLSchema#date" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasMaximalPrice" : [ { "@value" : 75.62000274658203 , "@type" : "http://www.w3.org/2001/XMLSchema#float" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasReimbursementAmount" : [ { "@value" : 60.70000076293945 , "@type" : "http://www.w3.org/2001/XMLSchema#float" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "POR TBL FLM 30X12.5MG" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0121352",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "APO-LOSARTAN 12,5 MG" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/C09CA01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "HYPOTENSIVA" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC159656_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "28" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Peror\u00E1ln\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "12.5MG" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : "-\tL\u00E9\u010Dba esenci\u00E1ln\u00ED hypertenze u dosp\u011Bl\u00FDch a d\u011Bt\u00ED a dosp\u00EDvaj\u00EDc\u00EDch ve v\u011Bku 6 a\u017E 18 let.\n-\tL\u00E9\u010Dba ren\u00E1ln\u00EDho onemocn\u011Bn\u00ED u pacient\u016F s\u00A0hypertenz\u00ED a diabetes mellitus 2. typu s\u00A0protein\u00FAri\u00ED \u2265\u00A00,5 g/den jako sou\u010D\u00E1st antihypertenzn\u00ED l\u00E9\u010Dby.\n-        L\u00E9\u010Dba chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED (u pacient\u016F \u2265 60 let), kdy\u017E l\u00E9\u010Dba inhibitory angiotenzin konvertuj\u00EDc\u00EDho enzymu (ACE ) nen\u00ED pova\u017Eov\u00E1na za vhodnou v d\u016Fsledku inkompatibility, zejm\u00E9na ka\u0161le, nebo kontraindikac\u00ED.  Pacienti se srde\u010Dn\u00EDm selh\u00E1n\u00EDm, kte\u0159\u00ED byli stabilizov\u00E1ni pomoc\u00ED ACE inhibitoru nesm\u011Bj\u00ED b\u00FDt na losartan p\u0159ev\u00E1d\u011Bni. Pacienti mus\u00ED m\u00EDt ejek\u010Dn\u00ED frakci lev\u00E9 komory \u2264 40 % a mus\u00ED b\u00FDt klinicky stabiln\u00ED a mus\u00ED m\u00EDt stanoven\u00FD l\u00E9\u010Debn\u00FD re\u017Eim pro chronick\u00E9 srde\u010Dn\u00ED selh\u00E1n\u00ED.\n-\tSn\u00ED\u017Een\u00ED rizika c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody u hypertonik\u016F s\u00A0hypertrofi\u00ED lev\u00E9 komory dokumentovan\u00E9 na EKG (viz bod 5.1 Studie LIFE, rasa).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "POR TBL FLM 28X12.5MG" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0121350",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "APO-LOSARTAN 12,5 MG" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/C09CA01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "HYPOTENSIVA" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC159656_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "100" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Peror\u00E1ln\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "12.5MG" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : "-\tL\u00E9\u010Dba esenci\u00E1ln\u00ED hypertenze u dosp\u011Bl\u00FDch a d\u011Bt\u00ED a dosp\u00EDvaj\u00EDc\u00EDch ve v\u011Bku 6 a\u017E 18 let.\n-\tL\u00E9\u010Dba ren\u00E1ln\u00EDho onemocn\u011Bn\u00ED u pacient\u016F s\u00A0hypertenz\u00ED a diabetes mellitus 2. typu s\u00A0protein\u00FAri\u00ED \u2265\u00A00,5 g/den jako sou\u010D\u00E1st antihypertenzn\u00ED l\u00E9\u010Dby.\n-        L\u00E9\u010Dba chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED (u pacient\u016F \u2265 60 let), kdy\u017E l\u00E9\u010Dba inhibitory angiotenzin konvertuj\u00EDc\u00EDho enzymu (ACE ) nen\u00ED pova\u017Eov\u00E1na za vhodnou v d\u016Fsledku inkompatibility, zejm\u00E9na ka\u0161le, nebo kontraindikac\u00ED.  Pacienti se srde\u010Dn\u00EDm selh\u00E1n\u00EDm, kte\u0159\u00ED byli stabilizov\u00E1ni pomoc\u00ED ACE inhibitoru nesm\u011Bj\u00ED b\u00FDt na losartan p\u0159ev\u00E1d\u011Bni. Pacienti mus\u00ED m\u00EDt ejek\u010Dn\u00ED frakci lev\u00E9 komory \u2264 40 % a mus\u00ED b\u00FDt klinicky stabiln\u00ED a mus\u00ED m\u00EDt stanoven\u00FD l\u00E9\u010Debn\u00FD re\u017Eim pro chronick\u00E9 srde\u010Dn\u00ED selh\u00E1n\u00ED.\n-\tSn\u00ED\u017Een\u00ED rizika c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody u hypertonik\u016F s\u00A0hypertrofi\u00ED lev\u00E9 komory dokumentovan\u00E9 na EKG (viz bod 5.1 Studie LIFE, rasa).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "POR TBL FLM 100X12.5MG" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0121347",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "APO-LOSARTAN 12,5 MG" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/C09CA01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "HYPOTENSIVA" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC159656_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "21" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Peror\u00E1ln\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "12.5MG" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : "-\tL\u00E9\u010Dba esenci\u00E1ln\u00ED hypertenze u dosp\u011Bl\u00FDch a d\u011Bt\u00ED a dosp\u00EDvaj\u00EDc\u00EDch ve v\u011Bku 6 a\u017E 18 let.\n-\tL\u00E9\u010Dba ren\u00E1ln\u00EDho onemocn\u011Bn\u00ED u pacient\u016F s\u00A0hypertenz\u00ED a diabetes mellitus 2. typu s\u00A0protein\u00FAri\u00ED \u2265\u00A00,5 g/den jako sou\u010D\u00E1st antihypertenzn\u00ED l\u00E9\u010Dby.\n-        L\u00E9\u010Dba chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED (u pacient\u016F \u2265 60 let), kdy\u017E l\u00E9\u010Dba inhibitory angiotenzin konvertuj\u00EDc\u00EDho enzymu (ACE ) nen\u00ED pova\u017Eov\u00E1na za vhodnou v d\u016Fsledku inkompatibility, zejm\u00E9na ka\u0161le, nebo kontraindikac\u00ED.  Pacienti se srde\u010Dn\u00EDm selh\u00E1n\u00EDm, kte\u0159\u00ED byli stabilizov\u00E1ni pomoc\u00ED ACE inhibitoru nesm\u011Bj\u00ED b\u00FDt na losartan p\u0159ev\u00E1d\u011Bni. Pacienti mus\u00ED m\u00EDt ejek\u010Dn\u00ED frakci lev\u00E9 komory \u2264 40 % a mus\u00ED b\u00FDt klinicky stabiln\u00ED a mus\u00ED m\u00EDt stanoven\u00FD l\u00E9\u010Debn\u00FD re\u017Eim pro chronick\u00E9 srde\u010Dn\u00ED selh\u00E1n\u00ED.\n-\tSn\u00ED\u017Een\u00ED rizika c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody u hypertonik\u016F s\u00A0hypertrofi\u00ED lev\u00E9 komory dokumentovan\u00E9 na EKG (viz bod 5.1 Studie LIFE, rasa).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "POR TBL FLM 21X12.5MG" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0121351",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "APO-LOSARTAN 12,5 MG" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/C09CA01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "HYPOTENSIVA" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC159656_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "21" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Peror\u00E1ln\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "12.5MG" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : "-\tL\u00E9\u010Dba esenci\u00E1ln\u00ED hypertenze u dosp\u011Bl\u00FDch a d\u011Bt\u00ED a dosp\u00EDvaj\u00EDc\u00EDch ve v\u011Bku 6 a\u017E 18 let.\n-\tL\u00E9\u010Dba ren\u00E1ln\u00EDho onemocn\u011Bn\u00ED u pacient\u016F s\u00A0hypertenz\u00ED a diabetes mellitus 2. typu s\u00A0protein\u00FAri\u00ED \u2265\u00A00,5 g/den jako sou\u010D\u00E1st antihypertenzn\u00ED l\u00E9\u010Dby.\n-        L\u00E9\u010Dba chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED (u pacient\u016F \u2265 60 let), kdy\u017E l\u00E9\u010Dba inhibitory angiotenzin konvertuj\u00EDc\u00EDho enzymu (ACE ) nen\u00ED pova\u017Eov\u00E1na za vhodnou v d\u016Fsledku inkompatibility, zejm\u00E9na ka\u0161le, nebo kontraindikac\u00ED.  Pacienti se srde\u010Dn\u00EDm selh\u00E1n\u00EDm, kte\u0159\u00ED byli stabilizov\u00E1ni pomoc\u00ED ACE inhibitoru nesm\u011Bj\u00ED b\u00FDt na losartan p\u0159ev\u00E1d\u011Bni. Pacienti mus\u00ED m\u00EDt ejek\u010Dn\u00ED frakci lev\u00E9 komory \u2264 40 % a mus\u00ED b\u00FDt klinicky stabiln\u00ED a mus\u00ED m\u00EDt stanoven\u00FD l\u00E9\u010Debn\u00FD re\u017Eim pro chronick\u00E9 srde\u010Dn\u00ED selh\u00E1n\u00ED.\n-\tSn\u00ED\u017Een\u00ED rizika c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody u hypertonik\u016F s\u00A0hypertrofi\u00ED lev\u00E9 komory dokumentovan\u00E9 na EKG (viz bod 5.1 Studie LIFE, rasa).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "POR TBL FLM 21X12.5MG" , "@language" : "cs" } ] }] }